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Available online 9 July 2016Evaluation of the reducing capacity of human gastric ﬂuid from healthy individuals, under fasted and fed condi-
tions, is critical for assessing the cancer hazard posed by ingested hexavalent chromium [Cr(VI)] and for develop-
ing quantitative physiologically-based pharmacokineticmodels used in risk assessment. In the present study, the
patterns of Cr(VI) reduction were evaluated in 16 paired pre- and post-meal gastric ﬂuid samples collected from
8 healthy volunteers. Human gastric ﬂuid was effective both in reducing Cr(VI), as measured by using the s-
diphenylcarbazide colorimetric method, and in attenuating mutagenicity in the Ames test. The mean (±SE)
Cr(VI)-reducing ability of post-meal samples (20.4 ± 2.6 μg Cr(VI)/mL gastric ﬂuid) was signiﬁcantly higher
than that of pre-meal samples (10.2 ± 2.3 μg Cr(VI)/mL gastric ﬂuid). When using the mutagenicity assay, the
decrease of mutagenicity produced by pre-meal and post-meal samples corresponded to reduction of 13.3 ±
1.9 and 25.6± 2.8 μg Cr(VI)/mL gastric ﬂuid, respectively. These data are comparable to parallel results conduct-
ed by using speciated isotope dilution mass spectrometry. Cr(VI) reduction was rapid, with N70% of total reduc-
tion occurringwithin 1min and 98% of reduction is achievedwithin 30minwith post-meal gastric ﬂuid at pH 2.0.
pH dependence was observed with decreasing Cr(VI) reducing capacity at higher pH. Attenuation of the muta-
genic response is consistentwith the lack of DNA damage observed in the gastrointestinal tract of rodents follow-
ing administration of ≤180 ppm Cr(VI) for up to 90 days in drinking water. Quantifying Cr(VI) reduction kinetics
in the human gastrointestinal tract is necessary for assessing the potential hazards posed by Cr(VI) in drinking
water.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Chromium is a naturally occurring element found in the earth and all
living beings, and it is also introduced into the environment by various
industries including welding, electroplating, painting and priming, and
production of pigments, ferrochromium/stainless steel, and chromate
chemicals (ATSDR, 2012; NIOSH, 2013). Originating from both natural
and anthropogenic sources, chromium is detected in groundwater,
drinking water, and soil, primarily in the trivalent [Cr(III)] and
hexavalent [Cr(VI)] forms (Oze et al., 2007; ATSDR, 2012; McNeil et
al., 2012; U.S. EPA, 2014). Cr(III) has limited acute and chronic toxicity,
and in 2-year cancer bioassays of the National Toxicology Programenza.Camoirano@unige.it
aestra78@yahoo.it (S. La
@unige.it (P. Zentilin),
.com (M. Suh),
. This is an open access article under(NTP), it was not carcinogenic to rodents (NTP, 2008b; Stout et al.,
2009a). In contrast, exposures with the drinking water to Cr(VI), as so-
dium dichromate dihydrate (SDD), caused an increase in small intesti-
nal cancers in B6C3F1 mice at ≥20 mg/L and oral cavity cancers in
F344/N rats at ≥60 mg/L (NTP, 2008a; Stout et al., 2009b). Notably,
these carcinogenic concentrations administered to rodents were at
least ~200,000 times higher than the average Cr(VI) concentrations
(~0.0001 mg/L) detected in the U.S. drinking water supply (McNeil et
al., 2012; U.S. EPA, 2014).
While Cr(III) enters the cell by passive diffusion, cellular uptake of
Cr(VI) is facilitated through anion transporters; thus, differences in tox-
icity between Cr(III) and Cr(VI) are largely due to the lower cell perme-
ability of Cr(III) (De Flora and Wetterhan, 1989; Collins et al., 2010;
ATSDR, 2012). The toxicity of Cr(VI) is mitigated by extracellular reduc-
tion of Cr(VI) to Cr(III) in bodily ﬂuids, including the gastric ﬂuid. The
earliest study suggesting Cr(VI) reduction by human gastric ﬂuid was
published 50 years ago by Donaldson and Barreras (1966) and showed
that infusion of Cr(VI) into the duodenum or jejunum resulted in a
greater excretion of chromium in urine, compared with oralthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tion by human gastric ﬂuid and, in some cases, detoxiﬁcation with mit-
igation of mutagenicity in the Ames test. In particular, De Flora and
Boido (1980) showed that pre-incubation with human gastric ﬂuid
from fasting subjects affected the mutagenicity of several chemical
agents in the Ames test, either in the sense of deactivation (sodium
azide and sodiumdichromate) or of stabilization (captan) or even of po-
tentiation (ICR-170) of mutagenic effects. For Cr(VI), gastric ﬂuid sam-
ples from 5 fasting individuals sharply decreased the mutagenic
response in the Ames test (S. typhimurium strain TA100), presumably
because gastric ﬂuid reduced Cr(VI) to the trivalent state. Heating the
gastric samples did not impact the assay results, but when sample pH
was increased, the decrease in positive response was attenuated (De
Flora and Boido, 1980). A further study showed that fasted gastric
juice samples from 4 other untreated subjects reduced 9.2 ±
0.4 μg Cr(VI)/mL (Petrilli and De Flora, 1982).
To date, De Flora et al. (1987) is the only detailed study that evaluat-
ed the circadian reduction of Cr(VI) in pre- and post-meal gastric ﬂuid
samples collected fromhuman volunteers, including one healthy volun-
teer and 16 hospitalized patients of both genders, most of whom were
suffering from duodenal ulcer. In that study, a nasogastric tube was po-
sitioned in the stomach for 24 h. A continuous intragastric pHmonitor-
ing was carried out, and gastric ﬂuid samples were aspirated hourly. A
total of 428 gastric ﬂuid samples were collected, centrifuged, and a
ﬁxed amount of ﬂuid (100 μL) was spiked ex vivo with 25 μL of a
200 μg/mL Cr(VI) solution (5 μg) to analyze Cr(VI) reduction within
60 min of reaction time by the s-diphenylcarbazide (DPC) colorimetric
method. In addition, the Ames reversion test using S. typhimurium strain
TA102 was conducted. The results showed that there was a signiﬁcant
decrease in Cr(VI) mutagenicity response in the presence of gastric
ﬂuid. Using the DPC colorimetric method, Cr(VI) reduction was ob-
served to be rapid in the ﬁrst 10 to 20min of reaction time. The baseline
Cr(VI) reduction quantiﬁed during the inter-digestive periods (fasted
states and mainly at night) was 8.3 ± 4.7 μg Cr(VI)/mL gastric ﬂuid, a
ﬁgure similar to the results of Petrilli and De Flora (1982). During the
post-prandial periods of approximately 3 to 4 h after each one of the 3
daily meals, reduction of 31.4 ± 6.7 μg Cr(VI)/mL gastric ﬂuid
(mean± SE) was observed, with peaks of 50 to 60 μg Cr(VI)/mL gastric
ﬂuid. In parallel, post-meal samples were signiﬁcantly more effective
than pre-meal samples in attenuating Cr(VI) mutagenicity. As checked
in 3 subjects, inhibition of Cr(VI) mutagenicity by gastric ﬂuid was sig-
niﬁcantly enhanced by stimulating gastric acid secretion with
pentagastrin. Similar to De Flora and Boido (1980), a statistically signif-
icant decrease in Cr(VI) reduction was observed when the pH of the
post-meal samples was increased to 7.0 (De Flora et al., 1987).
Based on the above data, taking into account that in a fasting individ-
ual the daily gastric secretion is 1000–1500 mL (Kirsner, 1974), and in
the 4-h period after each meal an average amount of approximately
800 mL is additionally secreted, De Flora et al. (1997) calculated that
the overall Cr(VI) reduction by gastric ﬂuid may be estimated to be at
least 84–88 mL per day, even disregarding the amounts of Cr(VI) that
are reduced by food and beverages (Kerger et al., 1996).
Zhitkovich (2005) commented that reduction measures of De Flora
et al. (1987) based on the use of the DPC colorimetric method could
be in error. Speciﬁcally, he stated that the colorimetric reaction with
DPC to quantify Cr(VI), which is conducted in the presence of 8% sulfuric
acid, would overestimate the reducing capabilities in biological systems
because many organic molecules can reduce Cr(VI) in highly acid solu-
tions. Zhitkovich (2005) disregarded the fact that Cr(VI) reduction by
human gastric ﬂuid, as assessed by colorimetric analyses, had been con-
ﬁrmed by the parallel inhibition of Cr(VI) mutagenicity. In addition, the
hypothesis by Zhitkovich (2005) is not supported by any experimental
demonstration, whereas the DPC method to analyze Cr(VI) is consid-
ered a valid analytical method that has been used for many decades in
air, water, and soil samples to assess occupational and environmental
Cr(VI) exposures (e.g., EPA Method 3060A). Furthermore, measures ofCr(VI) reduction by the gastric ﬂuid from fasted pre-operative patients
was recently shown to be consistentwith theDe Flora et al. (1987)mea-
sures using speciated isotope dilution mass spectrometry (SIDMS)
(Kirman et al., 2013).
The goal of the present study was to evaluate Cr(VI) reduction pat-
terns by paired human gastric ﬂuid samples collected, under fasted
and fed conditions, fromhealthy individuals, in the absence of anymed-
ical treatment. We also explored the time and pH dependence of the re-
action of Cr(VI) in gastric ﬂuid. Cr(VI) reduction and mitigation of its
mutagenicity were evaluated in parallel by using the DPC colorimetric
method and the Ames test, and most samples were also analyzed by
SIDMS (see Kirman et al., 2016). The results conﬁrmed the ability of
human gastric juice to reduce Cr(VI) and to inhibit its biological activity,
with signiﬁcant differences between fasted and fed samples. Under-
standing Cr(VI) reduction kinetics is critical for assessing the potential
hazards posed by Cr(VI) in drinking water at environmentally-relevant
levels.
2. Materials and methods
2.1. Collection and preparation of human gastric ﬂuid samples
Paired pre- and post-meal gastric ﬂuid samples were collected from
9 healthy volunteers aged 26 to 34 years (average age: 29.7 years). The
study protocolwas approved by theUniversity of Genoa Ethics Commit-
tee and performed according to the Declaration of Helsinki. All study
participants signed an informed consent form. Without causing harm
or much discomfort, nasogastric tubes (Bicakcilar Nasogastric Cateter
Levin), having 4 mm diameter and 1210 mm length, were inserted
into each study participant to obtain gastric ﬂuid samples. Pre-meal
samples were collected after overnight fasting, and post-meal samples
were collected 1.5 h after completion of lunch. The average caloric in-
take of the meal was 700 kcal, with the following standardized compo-
sition: pasta 70 g (238 kcal), roast meat or escalope 100 g (100–
110 kcal), tomatoes 100 g (17 kcal), jam pastry (190 kcal), plus
condiments.
All gastric ﬂuid samples were centrifuged at 1000 ×g for 10 min in
order to remove gross food particles, and the supernatant portions
were used. The pH of each gastric ﬂuid sample wasmeasuredwith indi-
cator strip in the ranges 0–6, 0–2.5, and 2.5–4.5 (E. Merck, Darmstadt,
Germany). The centrifuged samples were then divided into 1-mL ali-
quots and stored at −20 °C. The samples from one study participant
was too viscous to be pipetted and was discarded. Hence, a total of 16-
paired gastric ﬂuid samples (pre- and post-meal) from 8 individuals
(6 males and 2 females) were tested in this study.
2.2.Measurement of Cr(VI) reduction in human gastric ﬂuid by theDPC col-
orimetric method
Several preliminary experiments were conducted to identify the op-
timal Cr(VI) concentration and gastric ﬂuid sample volumes to yield lin-
ear dose–response curves for Cr(VI) reduction as well as the optimal
amounts of gastric juice to be challenged with the highest sodium di-
chromate dihydrate (SDD) dose (data not shown). These experiments
showed that the optimal concentration of Cr(VI) to be tested was 6 μg
SDD (Sigma, Saint Louis, MO, USA) in 100 μL deionized water. Thus,
each reaction mixture contained 6 μg SDD in 100 μL deionized water,
which was added to: 1) 50 μL gastric ﬂuid; 2) 25 μL gastric ﬂuid plus
25 μL deionized water; 3) 12.5 μL gastric ﬂuid plus 37.5 μL deionized
water; or 4) 50 μL deionized water. As such, the total volume for a gas-
tricﬂuid reactionmixturewas 150 μL. Formost experiments, incubation
of Cr(VI) in gastric ﬂuid was conducted at 37 °C for 60min. However, to
examine time dependence of Cr(VI) reduction, various reaction times
from 1 to 60 min were also tested using a pooled sample (pH 2.0)
made from post-meal gastric ﬂuid.
Table 1
Amounts of Cr(VI) reduced permL of pre-meal and post-meal paired gastric juice samples,
as assessed either by colorimetric method (DPC reagent) or by mutagenicity assay (S.
typhimurium strain TA104, in the absence of S9 mix).
Sample
Identiﬁcation
code
Collection
time pH
Cr(VI) reduced (μg/mL)
Colorimetric
method
Mutagenicity
assay
No. 1 ASS Pre-meal 1.6 5.5 7.8
No. 2 ASS Post-meal 1.9 26.6 38.9
No. 3 GEM Pre-meal 1.9 5.6 10.8
No. 4 GEM Post-meal 3.5 10.9 18.8
No. 7 SAM Pre-meal 1.9 20.2 22.0
No. 8 SAM Post-meal 1.9 29.7 31.6
No. 11 MAR Pre-meal 1.6 9.7 11.3
No. 12 MAR Post-meal 2.2 21.6 20.2
No. 13 BOD Pre-meal 1.6 4.6 13.4
No. 14 BOD Post-meal 2.2 26.6 20.3
No. 15 BRU Pre-meal 2.5 2.3 6.0
No. 16 BRU Post-meal 3.0 9.3 35.0
No. 17 DEL Pre-meal 1.6 17.6 18.1
No. 18 DEL Post-meal 3.5 18.6 20.8
No. 19 MAZ Pre-meal 1.6 17.1 16.7
No. 20 MAZ Post-meal 2.0 19.7 19.3
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ples that were either pre-heated at 56 °C for 30 min or at 70 °C for
20 min, or kept at 20 °C for 10 days to evaluate the effect of heating
and storage at room temperature. The effect of freeze and thaw cycles
on Cr(VI) reduction was also evaluated.
In addition, post-meal gastric ﬂuid samples were pooled yielding
pH 2.5. Varying amounts of the pooled samples (0, 12.5, 25, and 50 μL
as described above) were used to investigate the pH dependence of
Cr(VI) reduction in gastric ﬂuid. Speciﬁcally, 6 μg SDD in acidiﬁed deion-
ized water at pH 2.0 or in Mcilvaine's citrate/phosphate buffer, achiev-
ing pH values of 2.0 to 8.0, were added to the pooled samples at 37 °C
for 60 min of reaction time to test the pH dependence of Cr(VI) reduc-
tion in gastric juice.
To analyze Cr(VI) reduction by the DPC colorimetric method, after 0
to 60 min of reaction time, all samples were transferred to an ice-cold
bath. The content of each reaction mixture sample was divided into 2
cuvettes. The cuvettes were ﬁlled with 2.5 mL of DPC reagent (Sigma,
Saint Louis, MO, USA), consisting of 40 mg DPC in 100 mL of 8% sulfuric
acid, 19% ethanol, and 73% water. Another set of cuvettes, used as
blanks, were ﬁlled with 2.5 mL of the same sulfuric acid-ethanol mix-
ture, but without DPC. After 15 min at room temperature, the resulting
Cr(VI)-DPC complex was measured at 540 nm in a Nano-Drop® ND-
1000 spectrophotometer (Thermo Fisher Scientiﬁc, Wilmington, DE,
USA), and the optical density (OD) of blanks was subtracted from the
OD of gastric ﬂuid samples.
2.3. Mutagenicity of Cr(VI) in Ames reversion test in the presence of human
gastric ﬂuid
The Ames reversion test was conducted using the S. typhimurium
strain TA104 that carries the hisG428 mutation (Marnett et al., 1985).
All assays were performed in the absence of exogenous metabolic sys-
tem (S9 mix), which is known to mitigate Cr(VI) mutagenicity (De
Flora, 1978; Petrilli and De Flora, 1978; NTP, 2008b). Gastric ﬂuid sam-
ple preparations, i.e., mixtures of 6 μg SDD in 100 μL deionizedwater and
varying amounts of gastric ﬂuid and deionized water that were used for
the DPC colorimetric method, were also applied to the Ames reversion
tests. After 60min of reaction time at 37 °C, all gastricﬂuidmixture sam-
ples were assayed according to the standard plate incorporation test
(Maron and Ames, 1983), using 3 replicate plates per mixture. Cr(VI)-
free plates were also tested to evaluate the number of spontaneous re-
vertants. Cr(VI) added to a solution without gastric ﬂuid was also in-
cluded as a positive control in the Ames reversion test.
The results from both experimental approaches (DPC colorimetric
method and Ames reversion test) were used to create regression lines
for each gastric ﬂuid sample and quantify Cr(VI) reduction capacity
(see Results). For the Ames assay, the number of S. typhimuriumhis− re-
vertantswasused instead of OD values tomake the calculations (see Re-
sults). Pair-wise t-tests were conducted to compare Cr(VI) reduction
between pre- and post-meal samples and between the two assays.
Pair-wise t-tests were conducted using Graphpad Prism 6 for Mac
(http://www.graphpad.com).
3. Results
3.1. Reduction of Cr(VI) in pre- and post-meal human gastric ﬂuid samples
Several preliminary assays were carried out in order to assess the
optimal experimental conditions (data not shown). Thereafter, in
order to generate comparative data, we tested all 16 gastric juice sam-
ples in a single experiment using the colorimetric method and, in a sep-
arate aliquot, using themutagenicity assay. The results of these analyses
are shown in Table 1, alongwith the pHof the examined samples,which
ranged between 1.6 and 2.5 for pre-meal gastric ﬂuid samples, and be-
tween 1.9 and 3.5 for the post-meal samples. With both experimental
approaches, we calculated the regression line and then derived eitherthe Cr(VI) reducing ability or the loss of mutagenicity of each sample
after 60 min of contact with varying amounts of gastric ﬂuid (0, 12.5,
25, and 50 μL) at 37 °C. To give an example, the regression line equation
for sample No. 1 is y =−0.0003x+ 0.114, where y is the SDD dose (in
μg) and x is the gastric ﬂuid amount (in μL). For reducing all 6 μg SDD
present in the mixture, the equation will be 0 = −0.0003x + 0.114,
and hence x = 380 μL. This means that we need 380 μL gastric ﬂuid to
reduce 6 μg SDD. Bymaking the proportion, 1mL of gastric juicewill re-
duce 15.8 μg SDD. Because Cr(VI) is the 34.9% of the SDD molecule, the
ﬁnal result is that 1mL of that gastric juice sample reduces 5.5 μg Cr(VI),
as shown in Table 1. Similar calculations were made by using the muta-
genicity assay, except that, instead of using OD values, we used the
number of S. typhimurium his− revertants. The regression lines generat-
edwith all samples, both using the colorimetric test and theAmes assay,
are shown in Supplemental Table 1.
From the observation of Table 1 it is evident that, irrespective of the
experimental approach, the post-meal samples were consistently more
efﬁcient than the corresponding pre-meal samples in reducing Cr(VI)
and in inhibiting its mutagenicity. The mean (±SE) Cr(VI) reducing
ability of pre-meal samples, as evaluated by means of the colorimetric
test, was 10.2 ± 2.39 μg Cr(VI)/mL gastric juice and that of post-meal
samples was 20.4 ± 2.61 μg Cr(VI). This difference was statistically sig-
niﬁcant (P b 0.01). When using the mutagenicity assay, the decrease in
mutagenicity produced by pre-meal samples and post-meal samples
corresponded to reduction of 13.3 ± 1.91 μg Cr(VI) and 25.6 ±
2.89 μg Cr(VI), respectively. Again, this difference was statistically sig-
niﬁcant (P b 0.01).
In general, results by the DPC colorimetric method indicated less
percent reduction than those determined by Ames reversion test, and
results were signiﬁcantly different for pre-meal samples (P = 0.03)
and for all samples combined (P= 0.04) between methods. However,
the results obtained by testing the 16 gastric juice samples by means
of the colorimetric test and those obtained by using the mutagenicity
assay were signiﬁcantly correlated (r= 0.675; P b 0.01).
3.2. Time and pH dependence of Cr(VI) reduction in pooled post-meal hu-
man gastric ﬂuid
Fig. 1 shows the DPC colorimetric results of varying the reaction
times for a pooled post-meal sample at pH 2.0. Cr(VI) reduction was
rapid; using the mass of Cr(VI) reduced in 60 min, it was observed
that after 30 min of contact, 98.3% of Cr(VI) had been reduced, after
15 min, 93.3% had been reduced, after 5 min, 78.4% had been reduced,
and after 1 min, 72.1% had been reduced.
Fig. 1. Time dependence of Cr(VI) reduction following preincubation at 37 °Cwith a gastric
juice pool (pH 2.0) for reaction times of 0 to 60 min in the DPC colorimetric method.
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ﬂuid
Fig. 2 shows the results of pH variations in gastric ﬂuid samples. It is
evident that Cr(VI) reduction capacity in human gastric ﬂuid becomes
progressively less efﬁcient at increasing pH. On a linear scale, we ob-
served a sharp decrease in Cr(VI) reduction starting at pH ≥ 4 (Fig. 2).
At pH 8.0, reduction capacity was decreased 3.6-times as compared to
that at pH 2.0 (5 μg Cr(VI)/mL gastric ﬂuid compared to 18 μg Cr(VI)/
mL gastric ﬂuid). As discussed in Part II (Kirman et al., 2016), no pH-de-
pendent inﬂection point in Cr(VI) reduction rate constantwas observed.3.4. Effect of heating, storage, and freeze-thawing the gastric ﬂuid samples
on Cr(VI) reduction
Cr(VI) reduction capacity was not affected by heating the gastric
ﬂuid samples either at 56 °C for 30 min or at 70 °C for 20 min (data
not shown). Two separate experiments (not shown) provided evidence
that Cr(VI) reductionwas not affected evenwhen sampleswere in stor-
age for 10 days at 20 °C in the dark (not shown). Likewise, Cr(VI) reduc-
tion was not affected by freeze-thaw cycles (freezing and thawing was
done 3 times for 4 gastric ﬂuid samples, data not shown).Fig. 2. pH dependence of Cr(VI) reduction after preincubation for 60 min with a gastric
juice pool, having an original pH of 2.5, before colorimetric analysis.4. Discussion
The present study evaluated for the ﬁrst time Cr(VI) reduction by
paired pre- and post-meal gastric ﬂuid samples collected from healthy
subjects. Our study results support the conclusions that (a) human gas-
tric ﬂuid is effective in reducing Cr(VI) and in inhibiting its mutagenic
activity; (b) even by removing gross food residues, the Cr(VI) reducing
activity is signiﬁcantly increased during the periods after meals; (c) at
relevant human exposure levels, Cr(VI) reduction is very rapid, much
faster than the time of permanence of food and beverages in the stom-
ach (see below); (d) Cr(VI) reduction is pH-dependent and is due to
thermostable components of this biological ﬂuid, and (e) the action of
these reducing components is favored by low pH and becomes less pro-
nounced at increasing pH.
In particular, the data resulting from the DPC colorimetric method
indicates that the reducing ability of samples from fasted subjects
accounted for 10.2 ± 2.39 μg Cr(VI)/mL gastric ﬂuid and that of post-
meal samples was 20.4 ± 2.61 μg Cr(VI)/mL gastric ﬂuid. By using the
Ames Salmonella test as a bioindicator of Cr(VI) reduction, the loss of
mutagenicity produced by pre-meal samples corresponded to 13.3 ±
1.91 μg Cr(VI), and the one produced by post-meal samples
corresponded to 25.6 ± 2.89 μg Cr(VI)/mL gastric ﬂuid. These ﬁgures
are comparable to those reported in our previous studies. In fact, we
previously reported that fasted gastric juice samples from 4 untreated
subjects reduced 9.2 ± 0.4 μg Cr(VI)/mL (Petrilli and De Flora, 1982).
In 1987, the circadian evaluation of Cr(VI) reduction by gastric juice
samples from hospitalized patients, mainly suffering from ulcers,
showed that the reducing activity of samples from fasting individuals
was 8.3 ± 4.7 μg Cr(VI)/mL, and during the 4 h after each meal Cr(VI)
reduction averaged 31.4 ± 6.7 μg Cr(VI)/mL.
Five of the 8 pre-meal samples examined in the present study by
using both the DPC colorimetric method and the Ames reversion test
(Nos. 7, 11, 15, 17, and 19) and 7 post-meal samples (Nos. 2, 4, 8, 12,
14, 16, and 20) were also analyzed by SIDMS. The modeled 1-hour re-
ducing capacity of Cr(VI) by SIDMS was 10.3 ± 3.0 μg Cr(VI)/mL gastric
ﬂuid for pre-meal samples and 20.4 ± 2.8 μg Cr(VI)/mL gastric ﬂuid for
post-meal samples (Kirman et al., 2016). Thus, the results obtained by
using in parallel two analytical methods and a biological system were
very similar. These ﬁndings demonstrate that DPC analysis may be
used to quantify the capacity for Cr(VI) reduction and that the concerns
raised by Zhitkovich (2005) are unfounded. In particular, several sepa-
rate experiments using different methodological approaches consis-
tently showed that the gastric ﬂuid from fasting individuals is able to
reduce about 10 μg Cr(VI)/mL. Because daily gastric secretion in a
fasting individual is 1000–1500mL, it can be calculated that the baseline
reduction in the human stomach is 10–15 mg Cr(VI)/day. The reducing
capacity of gastric ﬂuid collected from the same healthy subjects was
doubled when it was evaluated 1.5 h after a light meal. This ﬁgure can-
not be compared to the values recorded in ulcer patients. In the previous
study (De Flora et al., 1987), Cr(VI) reduction had been monitored at
multiple time points, and the peak of reduction was found to vary
from individual to individual during the 3–4-h period after each meal.
In any case, taking into account that approximately 800 mL gastric
ﬂuid is secreted during the 4-h period after eachmeal, the data generat-
ed in healthy subjects suggest that about 16 mg Cr(VI) are reduced in
the gastric environment after each meal.
Similar to the ﬁndings of previous studies (De Flora and Boido, 1980;
Petrilli and De Flora, 1982; De Flora et al., 1987), our study results also
indicate that human gastric ﬂuid is effective in attenuating response in
the Ames test. Mitigation of Cr(VI) mutagenicity by gastric ﬂuid in the
Ames assays are consistent with the lack of positive results in the in
vivo genotoxicity studies where Cr(VI) was administered by physiolog-
ically-relevant routes of exposure (e.g., ingestion) (De Flora et al., 2008;
NTP, 2007;O'Brien et al., 2013; Thompson et al., 2015a, 2015b, 2015c). It
is also notable that Cr(VI) reduction in our gastric ﬂuid samples was
very rapid, and at relevant exposure is expected to be nearly complete
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tying from the stomach is 12min in fasting individuals, while the transit
time for a meal in the stomach is approximately 4 h (Granger et al.,
1985). Even though pH is higher in the post-meal samples and large
food particles were removed by centrifugation, Cr(VI) reductionwas re-
markably increased (~50%) compared to the pre-meal samples. Hence,
our study results afﬁrm that Cr(VI) reduction capacity is affected largely
by the thermostable reducing agents present in the gastric ﬂuid.
The Ames results herein demonstrate the role that gastricﬂuid has in
protecting cells from Cr(VI) toxicity. Consistently, DNA damage mea-
sured by γ-H2AX immunostaining, micronucleus induction, and k-ras
codon 12 mutations are negative in the duodenum of B6C3F1 mice ex-
posed to ≤180 ppm Cr(VI) for up to 90 days (O'Brien et al., 2013;
Thompson et al., 2015a, 2015b). X-ray ﬂuorescence imaging of chromi-
um distribution within the intestinal mucosa indicates Cr signal in the
villi, but not in the crypt region of mice exposed to 180 mg/L Cr(VI)
(Thompson et al., 2015a, 2015b). This suggests that any unreduced
Cr(VI) poses little genotoxic risk to the long-lived stem cells of the
small intestine.
It is evident that, due to the lack of toxicity of Cr(III), reduction of
Cr(VI) in the stomach, and in other body compartments, represents de-
toxiﬁcation and introduces a threshold or nonlinear mechanism limit-
ing Cr(VI) toxicity, genotoxicity and carcinogenicity in vivo (De Flora,
2000). This longstanding observation was developed based on earlier
gastric reduction data and conﬁrmed with the current ﬁndings. With
reference to the De Flora et al. (1987) study, the IARC Working Group
“interpreted these ﬁndings as indicating mechanisms that limit the ac-
tivity of chromium(VI) compounds in vivo” (IARC, 1990). When setting
new standards for drinking water, the U.S. EPA acknowledged that “the
body's normal physiology provides detoxiﬁcation for chromium(VI),
which provides protection from the oral toxicity of Cr(VI)” (U.S. EPA,
1991). The Agency for Toxic Substances and Disease Registry indicated
that these “mechanisms limit the bioavailability and attenuate the po-
tential effects of chromium(VI) compounds in vivo” (ATSDR, 1993).
The European Food Safety Authority (EFSA) reported that “the determi-
nant of the genotoxic effects of Cr(VI) in vivo is the reductive capacity of
the gastrointestinal tract that may signiﬁcantly limit or fully prevent
Cr(VI) uptake in the blood and/or distribution to the target tissues
when administered orally” (EFSA, 2014).
Based on these mechanisms, it is very unlikely that drinking water
exposure to Cr(VI) poses a carcinogenic hazard, even at doses largely
exceeding the amounts found in drinkingwater supplies, which typical-
ly occur at average levels b0.001 mg/L. It is recognized that individuals
using PPIs have higher pH stomach conditions and thus reduce Cr(VI) at
lower rates as compared to non-users. Kirman et al. (2016) reported
stomach reduction data for three fasting PPI users with stomach pH of
5 to 7.5. The pH-dependent reduction ratemodel was able to predict re-
duction rates in PPI users, and as such, this subpopulation can be quan-
titatively evaluated in future risk assessments (Kirman et al., 2016).
Regarding incidental ingestion of Cr(VI) in the workplace from air-
borne exposures, a literature review and meta-analysis of oral cavity,
esophageal, stomach, small intestine, colon, and rectal cancers among
workers occupationally exposed to Cr(VI) during the period 1950–
2009 provided evidence that Cr(VI)-exposedworkers are not at a great-
er risk of cancers of these tissues than reference populations (Gatto et
al., 2010). This ﬁnding is supported by two recent updates of mortality
among very highly exposed cohorts of US chromate productionworkers
(Proctor et al., 2016; Gibb et al., 2015), neither of which found a signif-
icant increase in stomach cancer risk. In contrast, the meta-analysis by
Welling et al. (2015) among exposed workers concluded: “Overall,
these results suggest that Cr(VI) is a stomach carcinogen in humans,
which is consistent with the tumour results reported in rodent studies”.
The differences in ﬁndings between the Gatto et al. (2010) andWelling
et al. (2015) meta-analyses deserves further study, but likely results
from differences in inclusion criteria. Further, the statement by
Welling et al. (2015) that Cr(VI) is a stomach carcinogen in rodents isnot documented by any study. In fact, the only study that reported pos-
itive results in the forestomach (Borneff et al., 1968) suffered from a
number of inadequacies, as admitted by the authors themselves, to
such an extent that it was not even mentioned in the IARC (1990)
Monograph. On the other hand, the NTP (2008a) study did not observe
any tumorigenic effects in either the glandular stomach or forestomach
of rats andmice, even at very high Cr(VI) exposures (NTP, 2008a; Stout
et al., 2009b).
The conclusion of the NTP (2008a) study was that “Cr(VI) exposure
resulted in increased incidences of rare neoplasms of the squamous ep-
ithelium that lines the oral cavity (oralmucosa and tongue) inmale and
female rats, and of the epithelium lining the small intestine in male and
female mice” (NTP, 2008a; Stout et al., 2009b). In particular, an increase
of small intestine tumors only occurred at 20mgCr(VI)/L and higher. In-
creased carcinogenicity was not observed at the lowest concentrations
tested in the NTP (2008a) study, corresponding to 5–10 mg Cr(VI)/L
water. As Cr(VI) reduction in stomach ﬂuids has been shown to be con-
centration-dependent (Proctor et al., 2012; Kirman et al., 2012, 2013;
Schlosser and Sasso, 2014) and the exposures that caused cancer exceed
the drinking water exposures by orders of magnitude, mouse intestinal
tumors are not expected to be relevant for human exposures. This is in
agreement with negative genotoxicity in the forestomach, glandular
stomach and duodenum of mice receiving sodium dichromate with
the drinking water at 5 and 20 mg Cr(VI)/L (De Flora et al., 2008).
Studies have demonstrated inter-species differences in the gastric
reducing capacity and rate with mice b rats b humans (Kirman et al.,
2013; Sasso and Schlosser, 2015). Differences in the anatomo-histolog-
ical structures and functional properties of the stomach also contribute
to differences between rodents and humans species. First, the pH of the
gastric environment is higher in rodents than in humans. For the pur-
poses of developing a rodent physiologically-based pharmacokinetic
(PBPK) model, the pH of stomach contents (forestomach and stomach
combined) of rats and mice, of the same strains and in the conditions
of the NTP study, was reported as 4.25–4.5 (Proctor et al., 2012). Al-
though the pH of the rodent aglandular forestomach and glandular
stomach are likely to vary, the gastric pH of healthy volunteers in our
study was considerably lower, 1.6–2.5 in pre-meal samples and 1.9–
3.5 in post-meal samples. As reduction capacity is signiﬁcantly reduced
at higher pH, Cr(VI) reduction is expected to be less efﬁcient in rodents
than in humans at baseline pH. Second, there are major differences in
the anatomical and histological structure of the stomach of rodents
and humans, and diverging physiology concerning digestion of food
and transformation of ingested toxic substances. In humans the entire
stomach is secretory and has numerous prominent folds (rugae),
whereas in rodents the interior of the stomach has two distinctive re-
gions separated by a prominent limiting ridge. The forestomach has a
hard and stratiﬁed squamous epithelium, which is heavily corniﬁed,
2–3 layers thick, and devoid of glands andmuscularis mucosa. Converse-
ly, the glandular stomach, which empties into the duodenum, has a del-
icate secretory epithelium and rugae that are noticeable when the
stomach is empty (DeSesso and Jacobson, 2001). In fasting humans,
the half-time for saline emptying from the human stomach is 12 min,
while the transit time for a meal in the stomach is approximately 4 h
(Granger et al., 1985). In rodents, the forestomach, which constitutes
the 60% of the stomach area, functions as a reservoir of food, which is
transferred to the glandular stomach in case of metabolic necessities.
The quantity of chyme delivered to the duodenum is independent of
stomach ﬁlling and corresponds to the rodent actual energy require-
ments. Because mice are continuous feeders (de Zwart et al., 1999),
there are no post-meal peaks of gastric juice secretion that in humans
provide the bulk of Cr(VI) reduction.
It is well recognized that the detoxifying capacity of the gastric envi-
ronment is not inﬁnite (Proctor et al., 2012; Kirman et al., 2013). The
ﬁnding that small intestine lesions and tumors were detected in mice
exposed to Cr(VI) in drinking water (NTP, 2008a; Stout et al., 2009b)
suggests that, at high concentrations, the reducing capacity of the
118 S. De Flora et al. / Toxicology and Applied Pharmacology 306 (2016) 113–119mouse GI tract was likely exceeded allowing for high concentrations of
Cr(VI) to reach the intestine. Due to interspecies differences, the results
of the NTP (2008a) study cannot be transferred to the human situation.
Incidentally, tumors affecting the small intestine are extremely rare in
humans (NCI, 2016).
In conclusion, the results of the present study provide further evi-
dence and quantitative data that, as previously demonstrated in ulcer
patients, Cr(VI) reducing ability is remarkably increased after meals in
healthy individuals. Such a pH-dependent mechanism is quite efﬁcient
in humans and is expected to provide a formidable barrier limiting the
toxicity, genotoxicity, and carcinogenicity of Cr(VI) introduced by the
oral route. The data generated in the present studymay contribute to as-
sess the potential hazards posed by Cr(VI) in drinkingwater at environ-
mentally relevant levels and to develop pharmacokinetic models
predicting the Cr(VI) fate in the human stomach.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2016.07.004.
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